The oncological safety of Autologous Fat Grafting (AFG) remains a paramount concern, particularly in the context of malignancies like breast cancer, sarcoma, cancers of the head and neck, or skin cancer. Despite the widespread application in addressing volume defects and contour irregularities post-tumor surgery, tumor safety has not been conclusively established due to potential risks of cancer recurrence. Mitigation strategies include informed consent based on current evidence, adherence to procedural timing recommendations, accurate risk group identification, and meticulous fat graft preparation and application. Standardized and careful mechanical processing, such as Cell Enriched Lipotransfer (CELT), preserves tissue structure, contrasting enzymatic methods which disrupt cellular niches, potentially affecting tumor dynamics.